- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01182532
A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Mild Type of Hand, Foot, and Mouth Disease
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Anhui
-
Hefei, Anhui, China
- Anhui Provincial Children's Hospital
-
Hefei, Anhui, China
- The First Affiliated Hospital of Anhui College of Traditional Chinese Medicine
-
-
Beijing
-
Beijing, Beijing, China
- Beijing Ditan Hospital
-
Beijing, Beijing, China
- Beijing You-An Hospital
-
-
Chongqing
-
Chongqing, Chongqing, China
- Chongqing Hospital of Traditional Chinese Medicine
-
-
Fujian
-
Fuzhou, Fujian, China
- Fuzhou Infectious Disease Hospital
-
Xiamen, Fujian, China
- Xiamen Hospital of Traditional Chinese Medicine
-
-
Gausu
-
Lanzhou, Gausu, China
- First Hospital of Lanzhou University
-
-
Guangzhou
-
Shenzhen, Guangzhou, China
- Shenzhen Third People's Hospital
-
-
Hebei
-
Shijiazhuang, Hebei, China
- The Fifth Hospital of Shijiazhuang, Hebei
-
-
Hubei
-
Wuhan, Hubei, China
- Wuhan Hospital for Infectious Diseases
-
-
Inner Mongolia
-
Huhehaote, Inner Mongolia, China
- Huhehaote Second Hospital
-
-
Jiangxi
-
Nanchang, Jiangxi, China
- Ninth Hospital of Nanchang
-
-
Jilin
-
Changchun, Jilin, China
- Changchun Infectious Diseases Hospital
-
-
Ningxia Hui Autonomous
-
Yinchuan, Ningxia Hui Autonomous, China
- Ningxia Hui Autonomous Region Forth People's Hospital
-
-
Shaanxi
-
Xi'an, Shaanxi, China
- The Eighth Hospital of Xi'an City
-
-
Shanghai
-
Shanghai, Shanghai, China
- Shanghai Public Health Center
-
-
Sichuan
-
Chengdu, Sichuan, China
- Chengdu Hospital for Infectious Diseases
-
-
Xinjiang
-
Urumuqi, Xinjiang, China
- Xinjiang Hongxing Hospital
-
-
Yunnan
-
Kunming, Yunnan, China
- First Affiliated Hospital to Kunming Medical College
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- The Sixth People's Hospital of Hangzhou
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical diagnosis of severe hand-foot-mouth disease patients according to Hand-Foot-Mouth Disease Treatment Guidelines 2010 issued by China's Ministry of Health; More than 1/3 patients should be diagnosed by etiological examination.
- Less than 48 hours of occurrence of fever and/or occurrence of tetter or herpes.
- Age of 1-14 years.
- Patients or their guardians agree to participate in this study and signed the informed consent form.
Exclusion Criteria:
- Complicated with other serious primary diseases in organ such as congenital heart disease, chronic hepatitis, nephritis and blood diseases, etc.
- With history of allergies on traditional Chinese medicine.
- Patients or their guardians suffering from Psychiatric diseases.
- Attending other clinical studies on HFMD after diagnosed.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Western therapy
|
Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.
|
|
Experimental: TCM treatment
|
Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Gardenia jasminoides Ellis (rough Zhi Zi), Scutellaria baicalensis Georgi (Huang Qin), etc. Dosage: Adjusting by age and weight of patients. Decoction. |
|
Experimental: Western therapy plus TCM treatment
The combination of both western therapy and TCM treatment.
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
time to onset
Time Frame: 10 days
|
Refering to the length of time to bring down the fever by 0.5 degrees Celsius after the medicine is taken.
|
10 days
|
|
time of body temperature going back to normal
Time Frame: 10 days
|
Refering to the time of the armpit temperature of lower than 37.0 degrees Celsius, lasting for at least 24 hours, after the medicine is taken.
|
10 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
time of symptom disappearance
Time Frame: 10 days
|
Refering to the length of time when clinical symptoms and signs totally disappere after the medicine is used.
|
10 days
|
|
case severity rate
Time Frame: 10 days
|
Refering to the ratio of patient with mild type of HFMD to severe type, such as damage of central nervous system, pulmonary edema, heart failure, respiratory failure, etc.
|
10 days
|
|
time of tetter and oral ulcer disappearance
Time Frame: 10 days
|
Refering to the length of time when the tetter due to HFMD disappears, characterised by no new tetter and oral ulcer develops, scab(s) or dropping; and time of oral ulcer concrescence, etc.
|
10 days
|
|
direct medical cost
Time Frame: 10 days
|
Referring to the costs in the treatment of HFMD and relative disease, including the registration fee, examination fee, and drug fees, etc.
|
10 days
|
|
safety outcome
Time Frame: 10 days
|
Calculated by adverse event.
|
10 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Guoliang Zhang, An'Hui Chinese Medical College Affiliated No.1 Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 200907001-3
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.